Business Context and Reporting Period
This Form 8-K was filed by Nukkleus Inc. (NUKK) on September 15, 2025. The filing reports the entry into a material definitive agreement to acquire a controlling 100% interest in Star 26 Capital Inc. ("Star"), a defense acquisition company. The transaction is subject to customary closing conditions, including shareholder approval required under Nasdaq listing rules.
Key Financial Metrics and Transaction Terms
The filing details the consideration for the acquisition of Star rather than reporting standard operating financial metrics (revenue, profit, cash flow) for the period. The total consideration structure includes:
- Cash Payment: $5,000,000 (balance of purchase price) plus $3,000,000 additional cash.
- Debt Instruments: A 12-month promissory note for $16,000,000 and a 6-month promissory note for $3,000,000 accruing interest at 8%.
- Equity Issuance: 4,770,340 shares of Nukkleus common stock.
- Warrants: A five-year warrant to purchase 12,017,648 shares of common stock at an exercise price of $1.50 per share.
- Liquidated Damages: $3,000,000 payable to Star if the agreement is terminated due to Nukkleus's failure to perform, lack of shareholder approval, or delisting from Nasdaq.
Material Changes and Target Assets
The transaction represents a strategic shift to acquire Star's portfolio of defense and technology assets. Star currently holds:
- 100% of B. Rimon Agencies Ltd., an Israeli distributor of military-grade generators, masts, and lighting systems (including suppliers for "Iron Dome" launchers).
- 67% of Water.IO Ltd., an Israeli corporation focused on smart hydration technology.
- A convertible loan issued by I.T.S. Industrial Techno-logic Solutions Ltd., a manufacturer of electro-mechanical machines and assembly lines.
Menachem Shalom, Nukkleus's CEO and a director, is also the controlling shareholder and CEO of Star. Upon consummation, he will remain a controlling shareholder of Nukkleus.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking financial guidance or management commentary regarding future revenue projections. Key risks and contingencies identified include:
- Shareholder Approval: The transaction is contingent upon approval by Nukkleus shareholders.
- Listing Status: The transaction is contingent on Nukkleus shares remaining listed on Nasdaq.
- Related Party Transaction: The deal involves significant overlap in leadership and ownership between the acquirer and the target.
- Termination Liability: A specific financial penalty of $3,000,000 is triggered if the deal fails due to Nukkleus's actions or regulatory status.
Investor Verification Checklist
- Verify the full text of the Amended and Restated Securities Purchase Agreement (Exhibit 10.1) for detailed covenants and conditions.
- Confirm the status of the required shareholder vote and Nasdaq listing compliance.
- Assess the financial health and valuation of the target assets (Rimon, Water.IO, and I.T.S. loan) relative to the $21M debt and equity consideration.
- Review the potential dilution impact of issuing 4.77M shares and 12M warrants.
- Monitor the $3M liquidated damages exposure if the transaction is terminated.